Medicine and Dentistry
Pulmonary Hypertension
100%
Acetylsalicylic Acid
100%
Simvastatin
100%
Clinical Trial
75%
Thrombocyte Aggregation
26%
Endothelial Dysfunction
26%
Placebo
21%
Nitric Oxide
17%
Platelet
17%
Endothelin 1
17%
Statin
17%
Phase II Trials
8%
Pulmonary Vasculature
8%
Thrombosis
8%
Pulmonary Artery
8%
Brachial Artery
8%
Bioavailability
8%
Lifespan
8%
Receptor Antagonist
8%
PADGEM Protein
8%
Artery Blood Flow
8%
Vasoconstriction
8%
Prostacyclin Derivative
8%
Flow Mediated Dilatation
8%
Thrombocyte Function
8%
Mitogenesis
8%
Vascular Occlusion
8%
Heart Output
8%
Oxidative Stress
8%
Lung Vascular Resistance
8%
Endothelial Cell
8%
Endothelium Injury
8%
Pathophysiology
8%
Thromboxane B2
8%
Thromboxane A2
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
100%
Simvastatin
100%
Pulmonary Hypertension
100%
Clinical Trial
75%
Endothelial Dysfunction
26%
Placebo
21%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
17%
Nitric Oxide
17%
Endothelin 1
17%
P-Selectin
8%
Receptor Antagonist
8%
Thromboxane B2
8%
Thromboxane A2
8%
Bioavailability
8%
Thrombosis
8%
Pathophysiology
8%
Inflammation
8%
Endothelium Injury
8%
Phase II Trials
8%
Prostacyclin Derivative
8%
Blood Vessel Occlusion
8%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
75%
Simvastatin
75%
Thrombocyte Aggregation
28%
Statin
18%
Nitric Oxide
18%
Endothelin 1
18%
Platelet
18%
Vasoconstriction
9%
Receptor Antagonist
9%
Lifespan
9%
Mitogenesis
9%
Thrombocyte Function
9%
Vascularization
9%
Phase II Trials
9%
Heart Output
9%
Dilatation
9%
Artery Blood Flow
9%
Animal Models
9%
Prostacyclin
9%
Oxidative Stress
9%
P-Selectin
9%
Lung Vascular Resistance
9%
Thromboxane B2
9%
Thromboxane A2
9%
Metabolic Pathway
6%